Therapeutic Hypothermia in Perinatal Asphyxia

Rabindran¹, Gedam DS²

¹Dr. Rabindran, Consultant Neonatologist, Billroth Hospital, Chennai, India, Dr D Sharad Gedam, Professor of Pediatrics, L N Medical college, Bhopal, MP, India

Address for Correspondence: Dr Rabindran, E mail: rabindranindia@yahoo.co.in

Abstract

Therapeutic hypothermia for infants with perinatal asphyxia has been studied in several randomised controlled trials. There is convincing evidence that moderate therapeutic hypothermia (33-34°C for 72 h), when initiated within 6 h after birth among term & near-term infants (≥35 weeks) with moderate to severe HIE reduces the risk of death or major disability & increases the rate of disability-free survival at 6-7 years of age

Key words: Therapeutic hypothermia, Asphyxia, perinatal asphyxia.

Introduction

Asphyxia is a major problem worldwide as 10% to 60% of affected infants die, & at least 25% of survivors have long-term neurodevelopmental sequelae. Therapeutic hypothermia for infants with perinatal asphyxia has been studied in several randomised controlled trials. There is convincing evidence that moderate therapeutic hypothermia (33-34°C for 72 h), when initiated within 6 h after birth among term & near-term infants (≥35 weeks) with moderate to severe HIE reduces the risk of death or major disability & increases the rate of disability-free survival at 6-7 years of age. Hypothermia results in a graded reduction in cerebral metabolism, suppresses apoptotic processes & also suppresses the release of pro-inflammatory cytokines & interleukins. The target body temperature is 34.5 °C for selective head cooling & 33.5 °C for total body cooling. Active cooling should be done for 72 hours & then gradual rewarming is done over 12 hours. Whole body cooling provides homogeneous cooling whereas selective head cooling provides greater cooling to the periphery of the brain than to the deeper brain structures. Though there were no reported serious adverse effects in the initial pilot studies of hypothermia in newborns, potential side effects reported later include bradycardia, arrhythmias, Hypotension, Reduction in surfactant production, Altered coagulation cascade, Thrombocytopenia, Leukopenia, lactic acidosis, Hypokalaemia & Hypoglycaemia. With the development of newer modes of servo controlled hypothermia devices the cerebral insult due to asphyxia can be reduced & severe sequelae of HIE can be prevented.

Asphyxia-Problem Statement: Perinatal asphyxia affects 3-5 newborns per 1000 live births with subsequent moderate or severe hypoxic ischaemic encephalopathy (HIE) in 0.5 to 1 per 1000 live births [1,2]. HIE is a major problem worldwide as 10% to 60% of affected infants die, and at least 25% of survivors have long-term neurodevelopmental sequelae [3,4]. Globally, perinatal asphyxia is responsible for 42 million disability life adjusted years, double that due to diabetes & three quarters of that due to HIV/AIDS [5]. Almost one quarter of the world’s 4 million annual neonatal deaths are caused by perinatal asphyxia [6]. These account for as many deaths as does malaria.

Therapeutic Hypothermia-Evidence: Therapeutic hypothermia for infants with perinatal asphyxia has been studied in several randomised controlled trials (RCT) [7-10]. Meta-analyses show that therapeutic hypothermia increases survival with normal neurological function (pooled risk ratio of 1.53) with a number needed to treat (NNT) of 8 & in survivors reduces the rates of severedisability & cerebral palsy [11,12]. A systematic review of three trials showed a significant reduction of combined rate of death &
severe disability with NNT of 9 & increased normal survival (survival without cerebral palsy & with MDI & PDI >84 & normal vision & hearing) with a NNT of 8 [12]. In a Cochrane review of 11 RCT comprising 1505 infants with moderate/severe encephalopathy & evidence of intrapartum asphyxia, therapeutic hypothermia resulted in a statistically significant reduction in combined outcome of mortality or major neurodevelopmental disability to 18 months of age (RR 0.75, RD -0.15); NNT for an additional beneficial outcome being 7. Cooling resulted in statistically significant reductions in mortality (RR 0.75, RD -0.09); NNT 11 & significant reductions in neurodevelopmental disability among survivors (RR 0.77, RD -0.13); NNT 8 [13]. A 2013 Cochrane review found that therapeutic hypothermia is useful in full term babies with encephalopathy [13]. There is convincing evidence that moderate therapeutic hypothermia (33-34°C for 72 h), when initiated within 6 h after birth among term & near-term infants (≥35 weeks) with moderate to severe HIE reduces the risk of death or major disability [12,13,14] & increases the rate of disability-free survival at 6-7 years of age [10,15].

Hypothermia Trials: Cool Cap trial used selective head cooling with mild systemic hypothermia (rectal temperature 34-35°C) commenced within 5.5 hours of age for 72 hours & showed an independent protective effect of hypothermia on the primary outcome of death or disability at 18 months (odds ratio 0.52) [7,16]. NICHD trial of whole body cooling (oesophageal temperature 33.5°C for 72 h) showed a significant reduction in the risk of death & moderate to severe disability at 18 months in the hypothermia group [8]. TOBY trial of whole body cooling (rectal temperature 33.5°C for 72h) showed a significant improvement in neurologic outcome in survivors from the hypothermic group [10]. Neo Neuro Network study [17] & ICE trial [18] further support a beneficial effect of hypothermia.

Proposed Mechanisms of Hypothermia: Hypothermia results in a graded reduction in cerebral metabolism by approximately 5% for each 1°C decrease in body temperature [3,4,7,12,19] that slows cell depolarization, reduces accumulation of excitotoxic neurotransmitters (aspartate, glutamate, dopamine) [20-22] & suppresses oxygen free radical release [23] as well as lipid peroxidation of cell membranes thereby lowering production of toxic nitric oxide (NO) & free radicals [23]. It suppresses apoptotic processes in the developing brain via inhibition of caspase enzymes [13,24-26]. Cytochrome C translocation is diminished by hypothermia [26, 27] & there is increased expression of anti-apoptotic protein BCL-2 [28]. It also suppresses the release of pro-inflammatory cytokines & interleukins during reperfusion injury phase, thereby reducing direct neurotoxicity via suppression of microglial activation [29,30]. The simultaneous increase in cytotoxic oedema& loss of cerebral cortical activity that accompanies secondary energy failure is also prevented [31].

Cooling Protocol: The target body temperature is 34.5°C for selective head cooling & 33.5°C for total body cooling. Temperatures lower than 32°C are less neuroprotective & temperatures below 30°C are very dangerous with severe complications [32]. Therapeutic hypothermia must be started within the first 6 h after birth which is the therapeutic window for hypoxic-ischemic event. Active cooling should be done for 72 hours from the initiation of cooling with very strict control of newborn’s body temperature. Then gradual rewarming is done over 12 hours by increasing temperature by 0.5°C every 2 hours.

Eligibility/criteria for therapeutic hypothermia:

1) More than 35 weeks of gestation.
2) Less than 6 hours of age.
3) Presence of evidence of asphyxia - at least two of the following four criteria:
   i) Apgar less than 6 at 10 min or continued need for resuscitation with positive pressure ventilation with / without chest compressions at 10 min of age.
   ii) Any acute perinatal event that may result in HIE (i.e. Abruption placenta, cord prolapse, severe foetal heart rate abnormality).
   iii) Cord pH less than 7.0 or base deficit of 12 or more.
   iv) If cord pH is unavailable, arterial pH less than 7.0/BE more than12 mmol/L within 60 min.
4) Clinically defined moderate or severe HIE (stage 2 or 3 based on modified Sarnat Classification).
5) Moderate to severely abnormal background activity on amplitude-integrated EEG (i.e. discontinuous, burst suppression or low voltage +/- seizure activity).

Modes of Cooling: Therapeutic hypothermia lowers the temperature of vulnerable deep brain structures, basal
ganglia to 32-34 °C. Brain hypothermia can be achieved by cooling the body, cooling the head selectively, or by cooling the head & body together. Whole body cooling provides homogeneous cooling to all brain structures, including the peripheral & central brain regions, whereas selective head cooling provides greater cooling to the periphery of the brain than to the deeper brain structures [33]. The combination of head & body cooling minimizes the temperature gradients across the brain & also facilitates the cooling of the deeper regions. To provide adequate neuroprotection with minimal risk of systemic adverse effects, ideally the brain only should be cooled. However, in view of a temperature gradient between the cerebral cortex & deep grey nuclei, i.e. structures that are often affected in acute asphyxia, mild systemic hypothermia (34.5°C) is preferred to limit the steepness of the intra-cerebral gradient.

**Devices for Cooling:** Various devices have been used for therapeutic hypothermia.

1) Selective head cooling by circulating water at 10°C through a coil of tubing wrapped around the head (CoolCap). A servo-controlled overhead heater was used to maintain rectal temperature at 34°C to 35°C [16].

2) Placing a cap formed from cooled packs around the head at a temperature of 10°C, to maintain a nasopharyngeal temperature of 34°C to 35°C [34].

3) Placing infant on a water blanket pre-cooled to 5°C & the blanket temperature was servo-controlled to maintain an oesophageal temperature of 33.5°C [8].

4) Blowing cool air through a translucent perforated paper blanket placed over the infant to achieve the target rectal temperature between 33.0°C to 34.0°C [16]. Nowadays hypothermia is maintained with servo controlled systems aimed at reducing fluctuations in body temperature.

**Adverse Effects of Cooling:** There were no reported serious adverse effects in initial four pilot studies of hypothermia in newborns [35-38]. The potential side effects reported later include Delayed intracardiac conduction with sinus bradycardia [39,40], Prolonged QT interval, Ventricular arrhythmias, Reduced cardiac output, Hypotension, Hypertension, Reduction in surfactant production, Increase in pulmonary vascular resistance, Increase in oxygen consumption & oxygen requirement, Altered coagulation cascade & viscosity leading to coagulopathy that may be complicated by thrombus or haemorrhage, Anaemia, Thrombocytopenia, Leukopaenia with increased risk of sepsis, Renal impairment, Metabolic & lactic acidosis, Hypokalaemia, Hypoglycaemia, Impaired liver function, Increase in vascular resistance, Platelet dysfunction, Excessive fibrinolytic activity, Diuresis due to suppression of antidiuretic hormones, Pulmonary hypertension, Impaired leucocyte mobility & phagocytosis [16]. Adverse effects, such as sinus bradycardia, increased blood pressure and increased oxygen requirement, were all transient and reversible with re-warming [36]. Cooling in the presence of infection might be deleterious as hypothermia may impair innate immune function, including neutrophil migration and function [41]. When lowering the body temperature, blood becomes more viscous & the solubility of the gases in the blood increases; for example, in vivo values at 33.5°C of PaCO2 are approximately 0.83 the value read at 37°C. Correcting for temperature may result in an increase in PaCO2 with a resultant increase in cerebral blood flow, whereas not correcting may result in the opposite effect, i.e. hypoxia induced vasoconstriction. During hypothermia, there may be an increased risk of endotracheal tube obstruction due to sticky secretions which can be avoided by setting the temperature of the humidifier at 37°C. During re-warming, seizures, hypotension [42], hypoglycaemia or hypokalaemia can occur.

**Conclusion**

Therapeutic hypothermia is a proven therapy in perinatal asphyxia provided prompt selection of babies & religious monitoring of temperature is done. Strict surveillance for the development of adverse effects is mandatory. With the development of newer modes of servo controlled hypothermia devices the cerebral insult due to asphyxia can be reduced & severe sequelae of HIE can be prevented.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the Institutional Ethics Committee.

**References**

1. Costello AM, Manandhar DS. Perinatal asphyxia in less developed countries. Arch Dis Child Fetal Neonatal Ed. 1994 Jul;71(1):F1-3.
2. Snowden JM, Cheng YW, Kontgis CP, Caughey AB. The association between hospital obstetric volume and perinatal outcomes in California. Am J Obstet Gynecol. 2012 Dec;207(6):478.e1-7. doi: 10.1016/j.ajog.2012.09.029. Epub 2012 Oct 1.

3. Vannucci RC. Current and potentially new management strategies for perinatal hypoxic-ischemic encephalopathy. Pediatrics. 1990 Jun;85(6):961-8.

4. Robertson CM, Perlman M. Follow-up of the term infant after hypoxic-ischemic encephalopathy. Paediatr Child Health. 2006 May;11(5):278-82.

5. Lawn JE, Kinney M, Lee AC, Chopra M, Donnay F, Paul VK, Bhutta ZA, Bateman M, Darmstadt GL. Reducing intrapartum-related deaths and disability: can the health system deliver? Int J Gynaecol Obstet. 2009 Oct;107 Suppl 1:S123-40, S140-2. doi: 10.1016/j.ijgo.2009.07.021.

6. Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet. 2005 Mar 5-11;365(9462):891-900.

7. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005 Feb 19-25;365(9460):663-70.

8. Shankaran SLA, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duran S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH, National Institute of Child Health and Human Development Neonatal Research Network: Whole-body hypothermia for neonates with hypoxic ischemic encephalopathy. N Engl J Med. 2005 Oct 13;353(15):1574-84.

9. Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, Horgan MJ, Languani S, Bhatia JJ, Givelichian LM, Sankaran K, Yager JY. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol. 2005 Jan;32(1):11-7.

10. Azzopardi D, Strohm B, Edwards A, Dyet L, Halliday H, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, Group TS: Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009 Oct 1;361(14):1349-58. doi: 10.1056/NEJMoa0900854.

11. Shah PS. Hypothermia: a systematic review and meta-analysis of clinical trials. Semin Fetal Neonatal Med. 2010 Oct;15(5):238-46. doi: 10.1016/j.siny.2010.02.003. Epub 2010 Mar 7.

12. Edwards A, Brocklehurst P, Gunn A, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D: Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: Synthesis and meta-analysis of trial data. BMJ. 2010 Feb 9;340:c363. doi: 10.1136/bmj.c363.

13. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013 Jan 31;1:CD003311. doi: 10.1002/14651858.CD003311.pub3.

14. Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med. 2012 Jun 1;166(6):558-66. doi: 10.1001/archpediatrics.2011.1772.

15. Shankaran S, Pappas A, McDonald SA, Vohr BR, Hintz SR, Yolton K, Gustafson KE, Leach TM, Green C, Bara R, Petrie Huitema CM, Ehrenkranz RA, Tyson JE, Das A, Hammond J, Peralta-Carcelean M, Evans PW, Heyne RJ, Wilson-Costello DE, Vaucher YE, Bauer CR, Dusick AM, Adams-Chapman I, Goldstein RF, Guillet R, Papile LA, Higgins RD; Eunice Kennedy Shriver NICHD Neonatal Research Network. Childhood outcomes after hypothermia for neonatal encephalopathy. N Engl J Med. 2012 May 31;366(22):2085-92. doi: 10.1056/NEJMoa1112066.

16. Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants after perinatal asphyxia: a safety study. Pediatrics. 1998 Oct;102(4 Pt 1):885-92.

17. Jacobs S, Stewart M, Inder T et al. ICE: the Australian cooling trial for hypoxic-ischemic encephalopathy-in hospital outcomes. Proceedings of the Hot Topics in Neonatology Conference. Washington DC, 2008.
18. Simbruner G, Mittal R, Rohlman F, Muche R. European nEURO.network trial. Proceedings of the Hot Topics in Neonatology Conference. Washington DC, Dec 7-9 2008.

19. Ereclinska M, Thoresen M, Silver IA. Effects of hypothermia on energy metabolism in Mammalian central nervous system. J Cereb Blood Flow Metab. 2003 May;23(5):513-30.

20. Busto R, Globus MY, Dietrich WD, Martinez E, Valdés I, Ginsberg MD. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain. Stroke. 1989 Jul;20(7):904-10.

21. Thoresen M, Satas S, Puka-Sundvall M, Whitelaw A, Hallström A, Löberg EM, Ungerstedt U, Steen PA, Hagberg H. Post-hypoxic hypothermia reduces cerebrocortical release of NO and excitotoxins. Neuroreport. 1997 Oct 20;8(15):3359-62.

22. Nakashima K, Todd MM. Effects of hypothermia on the rate of excitatory amino acid release after ischemic depolarization. Stroke. 1996 May;27(5):913-8.

23. Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD. Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia. J Neurochem. 1995 Oct;65(4):1704-11.

24. Northington FJ, Graham EM, Martin LJ. Apoptosis in perinatal hypoxic-ischemic brain injury: how important is it and should it be inhibited? Brain Res Brain Res Rev. 2005 Dec 15;50(2):244-57. Epub 2005 Oct 10.

25. Ohmura A, Nakajima W, Ishida A, Yasuoka N, Kawamura M, Miura S, et al. Prolonged hypothermia protects neonatal rat brain against hypoxic-ischemia by reducing both apoptosis and necrosis. Brain Dev. 2005;27:517---26.

26. Edwards AD, Yue X, Squier MV, Thoresen M, Cady EB, Penrice J, Cooper CE, Wyatt JS, Reynolds EO, Mehmet H. Specific inhibition of apoptosis after cerebral hypoxia-ischaemia by moderate post-insult hypothermia. Biochem Biophys Res Commun. 1995 Dec 26;217(3):1193-9.

27. Xu L, Yenari MA, Steinberg GK, Giffard RG. Mild hypothermia reduces apoptosis of mouse neurons in vitro early in the cascade. J Cereb Blood Flow Metab. 2002 Jan;22(1):21-8.

28. Zhang, Z; Sobel, RA; Cheng, D; Steinberg, GK; Yenari, MA. (2001). "Mild hypothermia increases Bcl-2 protein expression following global cerebral ischemia. Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):75-85. doi:10.1016/S0169-328X(01)00247-9.

29. Cornette L. Therapeutic hypothermia in neonatal asphyxia. Facts Views Vis Obgyn. 2012;4(2):133-9.

30. Wassink G, Gunn ER, Drury PP, Bennet L, Gunn AJ. The mechanisms and treatment of asphyxial encephalopathy. Front Neurosci. 2014 Feb 27;8:40. doi: 10.3389/fnins.2014.00040. eCollection 2014.

31. Gunn AJ, Gunn TR, Gunning MI, Williams CE, Gluckman PD. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. Pediatrics. 1998 Nov;102(5):1098-106.

32. Silveira RC, Procianoy RS. Hypothermia therapy for newborns with hypoxic ischemic encephalopathy. J Pediatr (Rio J). 2015 Nov-Dec;91(6 Suppl 1):S78-83. doi: 10.1016/j.jped.2015.07.004. Epub 2015 Sep 4.

33. Laptook AR, Shalak L, Corbett RJ. Differences in brain temperature and cerebral blood flow during selective head versus whole-body cooling. Pediatrics. 2001 Nov;108(5):1103-10.

34. Simbruner G, Haberl C, Harrison V, Linley L, Willeitner AE. Induced brain hypothermia in asphyxiated human newborn infants: a retrospective chart analysis of physiological and adverse effects. Intensive Care Med. 1999 Oct;25(10):1111-7.

35. Azzopardi D, Robertson NJ, Cowan FM, Rutherford MA, Rampling M, Edwards AD. Pilot study of treatment with whole body hypothermia for neonatal encephalopathy. Pediatrics. 2000 Oct;106(4):684-94.

36. Thoresen M, Whitelaw A. Cardiovascular changes during mild therapeutic hypothermia and rewarming in infants with hypoxic-ischemic encephalopathy. Pediatrics. 2000 Jul;106(1 Pt 1):92-9.

37. Battin MR, Dezoete JA, Gunn TR, Gluckman PD, Gunn AJ. Neurodevelopmental outcome of infants treated with head cooling and mild hypothermia after perinatal asphyxia. Pediatrics. 2001 Mar;107(3):480-4.

38. Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, Stark AR, Tyson
JE, Poole K, Carlo WA, Lemons JA, Oh W, Stoll BJ, Papile LA, Bauer CR, Stevenson DK, Korones SB, McDonald S. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. Pediatrics. 2002 Aug;110(2 Pt 1):377-85.

39. Fugelseth D, Satas S, Steen PA, Thoresen M. Cardiac output, pulmonary artery pressure, and patent ductus arteriosus during therapeutic cooling after global hypoxia-ischaemia. Arch Dis Child Fetal Neonatal Ed. 2003 May; 88(3): F223–F228. doi: 10.1136/fn.88.3.F223

40. Zhou WH, Shao XM, Zhang XD, Chen C, Huang GY. [Effects of hypothermia on cardiac function in neonates with asphyxia]. Zhonghua Er Ke Za Zhi. 2003 Jun;41(6):460-2.

41. Biggar WD, Barker C, Bohn D, Kent G. Partial recovery of neutrophil functions during prolonged hypothermia in pigs. J Appl Physiol (1985). 1986 Apr;60(4):1186-9.

42. Thoresen M. Supportive care during neuroprotective hypothermia in the term newborn: adverse effects and their prevention. Clin Perinatol. 2008 Dec;35(4):749-63, vii. doi: 10.1016/j.clp.2008.07.018.

How to cite this article?
Rabindran, Gedam DS. Therapeutic Hypothermia in Perinatal Asphyxia: Int J Pediatr Res 2016;3(2):124-129. doi:10.17511/ijpr.2016.i02.10.